Early Phase Clinical Trials Unit START-Madrid-FJD, Fundación Jiménez Diaz University Hospital, Madrid, Spain.
Clin Cancer Res. 2021 May 15;27(10):2669-2671. doi: 10.1158/1078-0432.CCR-21-0168. Epub 2021 Mar 10.
Novel antibody formats such as bispecifics have increased risk of immunogenicity, impacting safety and efficacy. LY3415244, a novel T-cell immunoglobulin and mucin-domain-containing molecule-3 (TIM3)-PDL1 (programmed death (ligand) 1) bispecific caused neutralizing antibody-drug antibodies (ADA) in 12 of 12 patients and required study termination. Novel approaches are needed to ameliorate and manage this undesirable effect of therapeutic antibodies..
新型抗体形式，如双特异性抗体，增加了免疫原性风险，影响安全性和疗效。LY3415244 是一种新型 T 细胞免疫球蛋白和粘蛋白结构域包含分子-3（TIM3）-PDL1（程序性死亡（配体）1）双特异性抗体，在 12 名患者中的 12 名中引起中和抗体-药物抗体（ADA），导致研究终止。需要新的方法来改善和管理治疗性抗体的这种不良作用。
